Literature DB >> 24360173

[Comparison of long-term health-related quality of life in patients with different methods of reconstruction after oncologic esophagectomy].

Lin-jun Li1, Qing-chen Wu2, Cheng Zhang1, Min Zhang1, Li Qiang1, Ying-jiu Jiang1, Dan Chen1.   

Abstract

OBJECTIVE: To explore the effects of reconstructing method (narrow gastric tube (NGT) versus whole stomach (WS)) on health-related quality of life (HRQL) in patients during a 3-year follow-up.
METHODS: In a prospective randomized single-center study from 2007 to 2008, 104 patients underwent esophagectomy for cancer. They were divided into NGT (n = 52) and WS (n = 52) groups. To assess HRQL, a questionnaire in references to EORTC-QLQ-C30 and QLQ-OES18 was administered at 3 weeks, 6 months, 1 year, 2 year and 3 years post-operation. Their clinical data were collected prospectively and follow-up was performed regularly.
RESULTS: The patients in the NGT group reported significantly (P < 0.05) better average scores of HRQL at both 6 months and 1 year.However, no significant difference in average scores of HRQL was found at 3 years. Patients in the NGT group reported significantly (P < 0.05) better scores of reflux at 3 weeks, 6 months and 1 year.Nausea was the only item with significant difference on HRQL at 2 years and 3 years.No significant difference existed between two groups with regards to cumulative survival rate at 3 years.
CONCLUSION: No significant difference existed between two groups with regards to cumulative survival rate at 3 years. The patients with gastric tube reconstruction after oncologic esophagectomy present better HRQL.Further studies are warranted to perform survival analysis beyond 3 year post-operation.

Entities:  

Mesh:

Year:  2013        PMID: 24360173

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  1 in total

Review 1.  Gastric-tube versus whole-stomach esophagectomy for esophageal cancer: A systematic review and meta-analysis.

Authors:  Wenxiong Zhang; Dongliang Yu; Jinhua Peng; Jianjun Xu; Yiping Wei
Journal:  PLoS One       Date:  2017-03-07       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.